Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Regeneron Pharmaceuticals
Cemiplimab is a recombinant human IgG4 monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of the anti-tumor immune response. It is studied in melanoma, colon cancer and Merkel cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 31, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06246916 | Phase 3 | Melanoma | Recruiting | REGN |
| NCT07224022 | Phase 2 | Colon Cancer | Not yet recruiting | REGN |
| NCT07387198 | Phase 2 | Merkel Cell Carcinoma, Stage I | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colon CancerMelanomaMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage IINeoadjuvant Immunotherapy
Updated Nov 15, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →